Gastrointestinal Stromal Tumors (GIST);Gastrointestinale Stromatumoren (GIST)

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 4, 2004, Pages 327-331

  Reichardt, Peter ^a,b   Pink, D ^a   Mrozek, A ^a   Lindner, T ^a   Hohenberger, P ^b  

^a Med Klin Schwerpunkt Hamatologie   (Germany)

^b Section of Pathology   (Germany)

Author keywords

Gastrointestinal stromal tumor; GIST; Imatinib

Indexed keywords

EVEROLIMUS; FLT3 LIGAND; IMATINIB; MIDOSTAURIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C INHIBITOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB;

AGE DISTRIBUTION; ANTINEOPLASTIC ACTIVITY; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CATHETER ABLATION; CLINICAL FEATURE; DRUG RESEARCH; DUODENUM; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LASER SURGERY; LIVER METASTASIS; METASTASIS POTENTIAL; PERITONEUM METASTASIS; REVIEW; STOMACH; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; GASTROINTESTINAL NEOPLASMS; HUMANS; PATIENT CARE MANAGEMENT; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; STROMAL CELLS;

EID: 2542514804     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-812691     Document Type: Review

References (12)

1. Benjamin RS, Rankin C, Fletcher C et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 2003; 22: 814 (abstr 3271)
2. De Matteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58
3. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480
4. Demetri GD, George S, Heinrich MC et al. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol 2003; 22: 814 (abstr 3273)
5. Edmonson JH, Marks RS, Buckner JC et al. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002; 20: 853-854
6. Fletcher CDM, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465
7. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056
8. Judson I, Verweij J, van Oosterom A et al. Imatinib an active agent for gastrointestinal stromal tumors (GIST), but not for other soft tissue sarcoma subtypes not characterized for KIT and PDGF-R expression, results of EORTC phase II studies. Proc Am Soc Clin Oncol 2002; 21: 403 a
9. Kindblom LG, Meis-Kindblom J, Bümming P et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stomal cell tumors(GIST) - a population-based study of 600 cases. Ann Oncol 2002: 13 (Suppl. 5): 157
10. Van den Abbeele AD, Badawi RD, Cliche JP et al. 18F-FDG-PET predicts response to imatinib mesylate in patients with advanced gastrointestinal stromal tumors. Proc Am Soc Clin Oncol 2002; 21: 403 a
11. van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-1423
12. Verweij J, Casali PG, Zalcberg J et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc Am Soc Clin Oncol 2003; 22: 814 (abstr 3272)